Sanofi S.A.
Researches, develops, manufactures and markets therapeutic solutions including vaccines, immunology treatments, rare disease medicines, and oncology drugs.
As of Oct 15, 2026
Summary
Sanofi S.A. is a French pharmaceutical and healthcare company with a market capitalisation of €85.8 billion. The stock is trading at €71.82 with a neutral technical bias, having declined 12.3 percent over the past year despite a modest daily gain of 1.5 percent. The company's one-month performance of negative 3.2 percent suggests recent downward momentum that warrants attention from those monitoring its near-term trajectory.
Price history
As of Oct 14, 2026
Performance
-0.32%
+0.01%
-3.22%
-7.14%
-8.32%
-12.26%
As of Oct 14, 2026
Technical indicators
- 45.7
- 0.1Bullish
- 50: 74.61 · 200: 75.3Bearish
- €71.73 / €75.30
Technical Bias
Sanofi's technical picture is mixed: momentum shows some bullish traction via MACD, but the price sitting just above support whilst below both the 50 and 200-day moving averages tilts the balance bearish, whilst RSI sits neutral in the middle ground. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Oct 14, 2026
Fundamentals
- €85.8B
- 22.03
- €3.25
- 8.09%
- +14.6%
- €8.99B
- 0.28
- €69.75 – €86.32
- 5.76%
- May 5, 2026
- Oct 30, 2026 (14 days)
As of Oct 16, 2026
Upcoming catalysts
- Earnings report
As of Oct 16, 2026
Latest news
As of Oct 16, 2026
MonkeyTrade's Take on Sanofi S.A.
Short-term outlook
Sanofi's short-term setup leans mildly bearish: price sits below both its 50-day (€74.61) and 200-day (€75.30) averages, with RSI neutral at 45.7 and the stock down 3.2% over the past month, even though MACD shows a faint bullish tick. A break back above the €75.30 resistance would challenge this soft downtrend, while a slip under €71.73 support would confirm it. No near-term catalyst is in view, with earnings not due until October 30, 2026.
Medium-term outlook
Sanofi's fundamentals skew constructive for the medium term: 14.6% revenue growth alongside an 8.1% profit margin shows the business expanding profitably, and a 5.8% dividend yield rewards patience while the technical picture sits neutral. With a P/E of 22.03, the shares aren't priced as a bargain, so the balance tips toward steady rather than spectacular over the next few quarters. A clear break in margin trend would be the development to watch.
Key risks
- Sanofi's current share price of €71.82 sits close to its 52-week low of €69.75 and well below the high of €86.32, suggesting the stock has lost ground over the past year and may face continued pressure if sentiment doesn't improve.
- A profit margin of 8.1% is relatively thin for a major pharmaceutical company, leaving limited cushion if costs rise or pricing pressure increases.
- Recent trial setbacks at other drug developers, such as the failed study that hit Syndax Pharmaceuticals, highlight the binary risk inherent in pharma pipelines, a dynamic that applies to Sanofi's own late-stage research programmes.
- A price-to-earnings ratio of 22.03 implies the market has built in solid growth expectations, so any slowdown from the current 14
About Sanofi S.A.
Sanofi S.A. is a French pharmaceutical group listed on Euronext Paris under the ticker SAN, operating within the healthcare sector as a drug manufacturer. With a market capitalisation of €85.8 billion, it ranks among the larger players in its industry, reflecting its scale and established presence in global medicine production and distribution.
Looking at its key figures, Sanofi trades on a price-to-earnings ratio of 22.03, giving a sense of how the market currently values its earnings relative to its share price. Its dividend yield stands at +5.8%, a figure income-focused investors often pay attention to when assessing shareholder returns. Together, these metrics offer a snapshot of how the stock is positioned financially within the broader drug manufacturing landscape, without pointing to any particular direction for the shares.
How to trade Sanofi S.A.
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.